Abcam and Genedata Align on AI-Driven Antibody Development

The deployment of Genedata’s enterprise software at Abcam facilities in the UK, China, and the US establishes a unified digital backbone for the company’s development pipeline. By centralizing data from cross-functional teams, the platform enables automated tracking of sample histories and characterization data, replacing fragmented processes with a structured environment designed for AI-powered discovery.

Kaveh Kahen, President of Abcam, noted that the infrastructure provides the automation and connectivity necessary to scale operations in response to growing global demand. For Othmar Pfannes, President of Genedata, the partnership represents a strategic effort to generate actionable scientific insights at scale, ultimately reducing the time required to move from early discovery to high-quality research outcomes.